Ovarian Cancer Specialty Channel

Conference Coverage

Datopotamab Deruxtecan Shows Promise for Unresectable Advanced Endometrial and Ovarian Cancers

09/12/2024

According to results of the TROPION-2 study, datopotamab deruxtecan monotherapy demonstrated encouraging efficacy and safety among patients with recurrent endometrial or ovarian cancer.

According to results of the...

09/12/2024

Oncology

FDA Approval

FDA Approves New Formulation of Thiotepa for Patients With Breast and Ovarian Cancer

07/01/2024

Stephanie Holland ;

The FDA has approved the new drug application for SH-105, a liquid formulation of thiotepa, for the treatment of patients with breast and ovarian cancer.

The FDA has approved the new...

07/01/2024

Oncology

News

Omitting Lymphadenectomy Reduced Post-Operative Morbidity, Did Not Negatively Impact Survival for Patients With Advanced Epithelial Ovarian Cancer

06/18/2024

Allison Casey ;

According to results from the phase 3 CARACO trial, the omission of retroperitoneal and paraaortic lymphadenectomy during surgery for advanced epithelial ovarian cancer did not negative impact survival outcomes and reduced the frequency of...

According to results from the...

06/18/2024

Oncology

Conference Coverage

Batiraxcept Plus Paclitaxel for Patients With Platinum-Resistant Ovarian Cancer

06/13/2024

Allison Casey ;

According to phase 2 results, batiraxcept plus paclitaxel did not improve the survival outcomes among the overall cohort of patients with platinum-resistant ovarian cancer, but may benefit patients with AXL-high expression.

According to phase 2 results,...

06/13/2024

Oncology

Conference Coverage

Suvemcitug Plus Chemotherapy Improved Survival Outcomes Among Patients With Platinum-Resistant Ovarian Cancer

06/13/2024

Allison Casey ;

Results from the phase 3 SCORES trial found suvemcitug plus chemotherapy improved the progression-free survival, objective response rate, and disease control rate among patients with platinum-resistant ovarian cancer.

Results from the phase 3 SCORES...

06/13/2024

Oncology

Conference Coverage

Olaparib Alone As a Chemotherapy-Free Approach Post-Cytoreduction for Patients With Platinum-Sensitive High-Grade Serous Ovarian Cancer

06/03/2024

Allison Casey ;

According to phase 2 data to be reported at the 2024 ASCO Annual Meeting, olaparib following secondary cytoreduction may be as effective as chemotherapy plus olaparib while being less toxic among patients with resectable, platinum-sensitive,...

According to phase 2 data to be...

06/03/2024

Oncology

News

Trabectedin Did Not Improve Survival or Safety Among Patients With Recurrent Ovarian Cancer and BRCA-Mutation/BRCAness Phenotype

02/09/2024

Stephanie Holland ;

Results from the phase 3 MITO-23 study demonstrated trabectedin did not improve overall survival and showed a worse safety profile compared to standard chemotherapy among patients with recurrent ovarian cancer and BRCA-mutation/BRCAness...

Results from the phase 3 MITO-23...

02/09/2024

Oncology

Quiz

Front-Line Treatment Options for Ovarian Cancer

12/20/2023

Oncology

News

Mirvetuximab Soravtansine Improved Survival, Response Among Patients With Platinum-Resistant, FRα-Positive Ovarian Cancer

12/19/2023

Stephanie Holland ;

According to results from the phase 3 MIRASOL trial, mirvetuximab soravtansine significantly improved progression-free survival (PFS), overall survival (OS), and objective response, compared with chemotherapy among patients with...

According to results from the...

12/19/2023

Oncology

Conference Coverage

Front-Line Treatment Options for Ovarian Cancer

12/07/2023

Bradley J. Monk , MD;

At the Great Debates & Updates in Women’s Oncology meeting, Bradley Monk, MD, discussed molecular testing and advancements in front-line treatment for patients with advanced epithelial ovarian cancer.

At the Great Debates & Updates...

12/07/2023

Oncology

Quiz

New and Emerging Targeted Therapies for Relapsing Ovarian Cancer

11/29/2023

Oncology

News

FDA Approval

FDA Approves New Formulation of Thiotepa for Patients With Breast and Ovarian Cancer

07/01/2024

Stephanie Holland ;

The FDA has approved the new drug application for SH-105, a liquid formulation of thiotepa, for the treatment of patients with breast and ovarian cancer.

The FDA has approved the new...

07/01/2024

Oncology

News

Omitting Lymphadenectomy Reduced Post-Operative Morbidity, Did Not Negatively Impact Survival for Patients With Advanced Epithelial Ovarian Cancer

06/18/2024

Allison Casey ;

According to results from the...

06/18/2024

Oncology

Conference Coverage

Batiraxcept Plus Paclitaxel for Patients With Platinum-Resistant Ovarian Cancer

06/13/2024

Allison Casey ;

According to phase 2 results,...

06/13/2024

Oncology

Conference Coverage

Suvemcitug Plus Chemotherapy Improved Survival Outcomes Among Patients With Platinum-Resistant Ovarian Cancer

06/13/2024

Allison Casey ;

Results from the phase 3 SCORES...

06/13/2024

Oncology

Conference Coverage

Olaparib Alone As a Chemotherapy-Free Approach Post-Cytoreduction for Patients With Platinum-Sensitive High-Grade Serous Ovarian Cancer

06/03/2024

Allison Casey ;

According to phase 2 data to be...

06/03/2024

Oncology

News

Trabectedin Did Not Improve Survival or Safety Among Patients With Recurrent Ovarian Cancer and BRCA-Mutation/BRCAness Phenotype

02/09/2024

Stephanie Holland ;

Results from the phase 3 MITO-23...

02/09/2024

Oncology

News

Mirvetuximab Soravtansine Improved Survival, Response Among Patients With Platinum-Resistant, FRα-Positive Ovarian Cancer

12/19/2023

Stephanie Holland ;

According to results from the...

12/19/2023

Oncology

Conference Coverage

Front-Line Treatment Options for Ovarian Cancer

12/07/2023

Bradley J. Monk , MD;

At the Great Debates & Updates...

12/07/2023

Oncology

News

Ofranergene Obadenovec Plus Paclitaxel Did Not Improve Survival Outcomes Among Patients With Recurrent, Platinum-Resistant Ovarian Cancer

11/13/2023

Stephanie Holland ;

According to results from the phase 3 OVAL/GOG 3018 study, the addition of ofranergene obadenovec to paclitaxel did not improve progression-free survival (PFS) or overall survival (OS) among patients with recurrent platinum-resistant ovarian...

According to results from the...

11/13/2023

Oncology

Conference Coverage

Addition of Atezolizumab to Chemotherapy and Maintenance Niraparib Did Not Improve PFS or ORR in Late-Relapsing, Recurrent Ovarian Cancer

11/03/2023

Stephanie Holland ;

According to primary analysis results from the phase 3 ENGOT-Ov41/GEICO 69-O/ANITA study, the addition of atezolizumab to chemotherapy and maintenance niraparib did not significantly improve progression-free survival (PFS) or objective...

According to primary analysis...

11/03/2023

Oncology

Interactive Features

Quiz

Front-Line Treatment Options for Ovarian Cancer

12/20/2023

Oncology

Quiz

New and Emerging Targeted Therapies for Relapsing Ovarian Cancer

11/29/2023

Oncology

Quiz

Maintenance Olaparib Rechallenge for Ovarian Cancer

10/31/2023

Oncology

Quiz

Sleeping Beauty Mutagenesis in High-Grade Ovarian Cancer

05/16/2023

How is Sleeping Beauty mutagenesis used to research tumor progression and potentially develop targeted therapies for future treatments for high-grade ovarian cancer?

How is Sleeping Beauty...

05/16/2023

Oncology

Quiz

Quiz: FDA Approves Mirvetuximab Soravtansine

12/15/2022

What treatment must patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer have received prior to receiving mirvetuximab soravtansine?

What treatment must patients...

12/15/2022

Oncology

Quiz

Quiz: Hyperthermic Intraperitoneal Chemotherapy Agent of Choice

12/02/2022

What is the most prevalent chemotherapy option when providing HIPEC to patients with ovarian cancer?

What is the most prevalent...

12/02/2022

Oncology

Quiz

Quiz: Pafolacianine With Near-Infrared Imaging for Detecting Folate Receptor-Positive Ovarian Cancer

11/03/2022

A phase 3 open-label study found that a single infusion of pafolacianine with near-infrared imaging detected the presence of folate-positive ovarian cancer not detected by white light assessment and palpation in what percentage of patients?

A phase 3 open-label study found...

11/03/2022

Oncology

Quiz

Quiz: Promising Novel Therapy in Tough-to-Treat Ovarian Cancer

03/27/2022

True or false: Researchers at the SGO 2022 Meeting From report mirvetuximab soravtansine monotherapy demonstrated anti-tumor activity in previously treated patients with folate receptor alpha (FRα)-high platinum-resistant ovarian cancer.

True or false: Researchers at...

03/27/2022

Oncology

Test Your Knowledge

Quiz: A Common Thread in Rising Endometrial Cases in US Women

05/29/2021

Quiz: Among young adult women in the United States, the number of endometrial cancer cases has risen alongside rates of which of the following conditions?

Quiz: Among young adult women in...

05/29/2021

Oncology

Test Your Knowledge

Quiz: Is Intensive Follow-Up of Patients Treated for Endometrial Cancer Beneficial?

05/28/2021

True or False: Study findings presented at the 2021 ASCO Annual Meeting support the use of frequent routine imaging and laboratory exams in patients treated for endometrial cancer.

True or False: Study findings...

05/28/2021

Oncology

Recent News

FDA Approval

FDA Approves New Formulation of Thiotepa for Patients With Breast and Ovarian Cancer

07/01/2024

Stephanie Holland ;

The FDA has approved the new drug application for SH-105, a liquid formulation of thiotepa, for the treatment of patients with breast and ovarian cancer.

The FDA has approved the new...

07/01/2024

Oncology

News

Omitting Lymphadenectomy Reduced Post-Operative Morbidity, Did Not Negatively Impact Survival for Patients With Advanced Epithelial Ovarian Cancer

06/18/2024

Allison Casey ;

According to results from the...

06/18/2024

Oncology

News

Trabectedin Did Not Improve Survival or Safety Among Patients With Recurrent Ovarian Cancer and BRCA-Mutation/BRCAness Phenotype

02/09/2024

Stephanie Holland ;

Results from the phase 3 MITO-23...

02/09/2024

Oncology

News

Mirvetuximab Soravtansine Improved Survival, Response Among Patients With Platinum-Resistant, FRα-Positive Ovarian Cancer

12/19/2023

Stephanie Holland ;

According to results from the...

12/19/2023

Oncology

News

Ofranergene Obadenovec Plus Paclitaxel Did Not Improve Survival Outcomes Among Patients With Recurrent, Platinum-Resistant Ovarian Cancer

11/13/2023

Stephanie Holland ;

According to results from the...

11/13/2023

Oncology

Conference Coverage

Addition of Atezolizumab to Chemotherapy and Maintenance Niraparib Did Not Improve PFS or ORR in Late-Relapsing, Recurrent Ovarian Cancer

11/03/2023

Stephanie Holland ;

According to primary analysis...

11/03/2023

Oncology

Conference Coverage

Standard of Care Superior to Olaparib With or Without Cediranib Among Patients With Relapsed, Platinum-Sensitive Ovarian Cancer

10/26/2023

Stephanie Holland ;

According to data from the phase 3 NRG-GY004 trial, olaparib with or without cediranib did not improve overall survival when compared with standard of care for patients with platinum-sensitive, relapsed ovarian cancer.

According to data from the phase...

10/26/2023

Oncology

Conference Coverage

Maintenance Senaparib Improved PFS Among Patients With Newly Diagnosed, Advanced Ovarian Cancer

10/25/2023

Stephanie Holland ;

According to results from the phase 3 FLAMES study, maintenance senaparib in the first-line setting significantly reduced the risk of progression or death among patients with newly diagnosed, stage 3 to 4 high-grade serous or endometrioid...

According to results from the...

10/25/2023

Oncology

News

Hyperthermic Intraperitoneal Chemotherapy Plus Interval Cytoreductive Surgery Significantly Improved Long-Term Survival Outcomes in Advanced Ovarian Cancer

10/12/2023

Stephanie Holland ;

According to updated survival results from the phase 3 OVHIPEC-1 trial, the addition of hyperthermic intraperitoneal chemotherapy to interval cytoreductive surgery significantly improved long-term progression-free survival and overall...

According to updated survival...

10/12/2023

Oncology

News

Rechallenge With Olaparib Maintenance Improved PFS Among Patients With Previously Treated, Platinum-Sensitive Ovarian Cancer

10/10/2023

Stephanie Holland ;

Results from the OReO/ENGOT-ov38 trial demonstrated that rechallenging with olaparib in the maintenance setting improved progression-free survival among patients with previously treated, platinum-sensitive ovarian cancer, regardless of BRCA...

Results from the OReO/ENGOT-ov38...

10/10/2023

Oncology

News

Osimertinib Lacks Activity in Neoadjuvant Setting for Early-Stage Non-Small Cell Lung Cancer With EGFR Mutation

08/08/2024

Stephanie Holland ;

Results from a phase 2 study demonstrated that neoadjuvant osimertinib did not improve the major pathological response rate among patients with early-stage non-small cell lung cancer harboring an EGFR mutation.

Results from a phase 2 study...

08/08/2024

Oncology

FDA Approval

FDA Approves Denileukin Diftitox for Patients With R/R Cutaneous T-Cell Lymphoma

08/08/2024

Amber Denham ;

The US Food and Drug Administration approved novel immunotherapy denileukin diftitox-cxdl for the treatment of patients with relapsed/refractory cutaneous T-cell lymphoma after at least 1 prior systemic therapy.

The US Food and Drug...

08/08/2024

Oncology

News

Tailored Dose-Dense Chemotherapy Improved Survival Outcomes Among Patients With High-Risk Early Breast Cancer

08/07/2024

Stephanie Holland ;

According to results from the phase 3 PANTHER trial, tailored and dose-dense chemotherapy in the adjuvant setting improved survival outcomes compared to standard chemotherapy among patients with high-risk early breast cancer.

According to results from the...

08/07/2024

Oncology

News

Frontline Treatment Management for Patients With FL Reduces Risk of High-Grade Transformation to DLBCL

08/07/2024

Amber Denham ;

A recent study demonstrated that frontline treatment management reduced the risk of high-grade transformation to diffuse large B-cell lymphoma among patients with follicular lymphoma, but not among patients with marginal zone lymphoma.

A recent study demonstrated that...

08/07/2024

Oncology

News

Optimal Sotorasib Dose for Patients With KRAS G12C-Mutated Advanced Non-Small Cell Lung Cancer

08/07/2024

Stephanie Holland ;

Results from a phase 2 study found that 960 mg of sotorasib is preferable to 240 mg among patients with previously treated KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer.

Results from a phase 2 study...

08/07/2024

Oncology

FDA Approval

FDA Approves Vorasidenib for Patients With IDH1/IDH2-Mutated Grade 2 Astrocytoma or Oligodendroglioma

08/06/2024

Stephanie Holland ;

Based on results from the INDIGO trial, the FDA has approved vorasidenib for adult and pediatric patients 12 years and older with grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery.

Based on results from the INDIGO...

08/06/2024

Oncology

FDA Approval

FDA Approves Afamitresgene Autoleucel for Certain Unresectable or Metastatic Synovial Sarcoma

08/02/2024

Allison Casey ;

On August 2, 2024, the US Food and Drug Administration (FDA) granted accelerated approval to afamitresgene autoleucel for the treatment of adult patients with certain unresectable or metastatic synovial sarcomas who had received prior...

On August 2, 2024, the US Food...

08/02/2024

Oncology

FDA Approval

FDA Approves Dostarlimab Plus Chemotherapy for Patients With Primary Advanced or Recurrent Endometrial Cancer

08/01/2024

Allison Casey ;

The FDA approved dostarlimab plus carboplatin and paclitaxel, followed by single-agent dostarlimab for patients with primary advanced or recurrent endometrial cancer.

The FDA approved dostarlimab...

08/01/2024

Oncology

News

Iadademstat and Azacitidine Combination Therapy Demonstrates Manageable Safety, Promising Efficacy for Patients With Newly Diagnosed AML

08/01/2024

Amber Denham ;

The first-line combination of iadademstat and azacitidine demonstrates a manageable safety profile and promising results among patients with acute myeloid leukemia, according to phase 2 results from the ALICE trial.

The first-line combination of...

08/01/2024

Oncology

News

Effect of Food on Selumetinib Dosing for Adolescent Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas

08/01/2024

Allison Casey ;

In the phase 1 trial, the addition of a low-fat meal with doses of selumetinib did not significantly impact selumetinib exposure or gastrointestinal toxicities among adolescent patients with neurofibromatosis type 1 with plexiform...

In the phase 1 trial, the...

08/01/2024

Oncology